Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/105210
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.creatorKhan, SA-
dc.creatorLee, TKW-
dc.date.accessioned2024-04-12T06:50:48Z-
dc.date.available2024-04-12T06:50:48Z-
dc.identifier.urihttp://hdl.handle.net/10397/105210-
dc.language.isoenen_US
dc.publisherFrontiers Research Foundationen_US
dc.rightsCopyright © 2023 Khan and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.rightsThe following publication Khan SA and Lee TKW (2023) Identifying potential pharmacological targets and molecular pathways of Meliae cortex for COVID-19 therapy. Front. Immunol. 14:1128164 is available at https://doi.org/10.3389/fimmu.2023.1128164.en_US
dc.subjectCOVID-19en_US
dc.subjectDockingen_US
dc.subjectMeliae cortexen_US
dc.subjectPharmacologyen_US
dc.subjectPhytonutrientsen_US
dc.subjectTargetsen_US
dc.titleIdentifying potential pharmacological targets and molecular pathways of Meliae cortex for COVID-19 therapyen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume14-
dc.identifier.doi10.3389/fimmu.2023.1128164-
dcterms.abstractCoronavirus disease-19 (COVID-19), caused by SARS-CoV-2, has contributed to a significant increase in mortality. Proinflammatory cytokine-mediated cytokine release syndrome (CRS) contributes significantly to COVID-19. Meliae cortex has been reported for its several ethnomedical applications in the Chinese Pharmacopoeia. In combination with other traditional Chinese medicines (TCM), the Meliae cortex suppresses coronavirus. Due to its phytoconstituents and anti-inflammatory capabilities, we postulated that the Meliae cortex could be a potential therapeutic for treating COVID-19. The active phytonutrients, molecular targets, and pathways of the Meliae cortex have not been explored yet for COVID-19 therapy. We performed network pharmacology analysis to determine the active phytoconstituents, molecular targets, and pathways of the Meliae cortex for COVID-19 treatment. 15 active phytonutrients of the Meliae cortex and 451 their potential gene targets were retrieved from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) and SwissTargetPrediction website tool, respectively. 1745 COVID-19-related gene targets were recovered from the GeneCards. 104 intersection gene targets were determined by performing VENNY analysis. Using the DAVID tool, gene ontology (GO) and KEGG pathway enrichment analysis were performed on the intersection gene targets. Using the Cytoscape software, the PPI and MCODE analyses were carried out on the intersection gene targets, which resulted in 41 potential anti-COVID-19 core targets. Molecular docking was performed with AutoDock Vina. The 10 anti-COVID-19 core targets (AKT1, TNF, HSP90AA1, IL-6, mTOR, EGFR, CASP3, HIF1A, MAPK3, and MAPK1), three molecular pathways (the PI3K-Akt signaling pathway, the HIF-1 signaling pathway, and the pathways in cancer) and three active phytonutrients (4,8-dimethoxy-1-vinyl-beta-carboline, Trichilinin D, and Nimbolin B) were identified as molecular targets, molecular pathways, and key active phytonutrients of the Meliae cortex, respectively that significantly contribute to alleviating COVID-19. Molecular docking analysis further corroborated that three Meliae cortex’s key active phytonutrients may ameliorate COVID-19 disease by modulating identified targets. Hence, this research offers a solid theoretic foundation for the future development of anti-COVID-19 therapeutics based on the phytonutrients of the Meliae cortex.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationFrontiers in immunology, 2023, v. 14, 1128164-
dcterms.isPartOfFrontiers in immunology-
dcterms.issued2023-
dc.identifier.scopus2-s2.0-85148361533-
dc.identifier.eissn1664-3224-
dc.identifier.artn1128164-
dc.description.validate202403 bcvc-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextFaculty of Science (1-ZVZY); PolyU Distinguished Postdoctoral Fellowship Scheme.en_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
fimmu-14-1128164.pdf13.95 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

15
Citations as of Jul 7, 2024

Downloads

3
Citations as of Jul 7, 2024

SCOPUSTM   
Citations

2
Citations as of Jul 4, 2024

WEB OF SCIENCETM
Citations

2
Citations as of Jul 4, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.